49 patents
Page 3 of 3
Utility
Somatostatin modulators and uses thereof
23 Mar 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Shimiao Wang, Yunfei Zhu
Filed: 7 May 19
Utility
Somatostatin Modulators and Uses Thereof
18 Mar 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon HAN, Sun Hee KIM, Yunfei ZHU
Filed: 16 Sep 19
Utility
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
17 Feb 20
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
Filed: 4 Jun 19
Utility
Process of Making Somatostatin Modulators
12 Feb 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jayachandra P. REDDY, Mahmoud MIRMEHRABI, Madhukar KOTA, Uttam DASH, Jian ZHAO, Yunfei ZHU
Filed: 2 Oct 19
Utility
Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists and Uses Thereof
8 Jan 20
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon HAN, Yunfei ZHU, Sun Hee KIM, Jian ZHAO, Shimiao WANG
Filed: 26 Aug 19
Utility
Somatostatin Modulators and Uses Thereof
8 Jan 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon HAN, Sun Hee KIM, Yunfei ZHU
Filed: 15 Sep 19
Utility
Somatostatin Modulators and Uses Thereof
18 Dec 19
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian ZHAO, Sangdon HAN, Sun Hee KIM, Shimiao WANG, Yunfei ZHU
Filed: 7 May 19
Utility
Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists and Uses Thereof
4 Dec 19
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon HAN, Yunfei ZHU, Sun Hee KIM, Jian ZHAO, Shimiao WANG
Filed: 4 Jun 19
Utility
Process of making somatostatin modulators
4 Nov 19
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jayachandra P. Reddy, Mahmoud Mirmehrabi, Madhukar Kota, Uttam Dash
Filed: 15 Jan 19